Please use this identifier to cite or link to this item:
DC FieldValueLanguage
dc.contributor.authorReis, Flávio-
dc.contributor.authorCampos, Maria Vitor-
dc.contributor.authorBastos, Margarida-
dc.contributor.authorAlmeida, Luis-
dc.contributor.authorLourenço, Margarida-
dc.contributor.authorFerrer-Antunes, Carlos A.-
dc.contributor.authorPalmeiro, Aida-
dc.contributor.authorSantos-Dias, José D.-
dc.contributor.authorMesquita, José F.-
dc.contributor.authorCarvalheiro, Manuela-
dc.contributor.authorTeixeira, Frederico-
dc.identifier.citationThe Journal of Clinical Endocrinology & Metabolism. 90:1 (2005) 98-105en_US
dc.description.abstractGH deficiency (GHD) is associated with a higher risk of vascular disease, whose pathophysiological mechanisms remains not yet fully elucidated. This study aimed to assess the main cardiovascular risk indexes, plasma catecholamines content, and the platelet function in childhood-onset GHD patients. Some of the main clinical examinations related with cardiovascular risk, plasma catecholamines content, as well as platelet intracellular free calcium concentration ([Ca(2+)](i)), whole-blood aggregation, and morphology were evaluated in childhood-onset GHD patients treated with GH for a variable period and off GH therapy for at least 2 yr before entry into study and in sex-, age-, and body mass index-matched control groups. Among the patients, group 1 (GHD-1) has recovered GH levels after withdrawal, whereas group 2 (GHD-2) has remained GH deficient. Minor differences on the cardiovascular risk indexes were observed between the groups. Plasma catecholamine concentrations in the GHD groups did not statistically differ from the control group, but higher adrenaline content was observed in the GHD-2 group when compared with the GHD-1 one. Basal and thrombin-evoked [Ca(2+)](i) and platelet aggregation were identical between the GHD-1 group and the matched control. However, the GHD-2 group has increased thrombin-evoked [Ca(2+)](i) (297.0 +/- 15.7 Deltanmol/liter; P < 0.01), collagen, and ADP-induced platelet aggregation (33.3 +/- 4.3 and 12.5 +/- 2.1 Omega, respectively; P < 0.05) vs. the control-2 group (Delta[Ca(2+)](i): 102.1 +/- 13.6 Deltanmol/liter; aggregation: 19.6 +/- 2.9 and 6.2 +/- 0.8 Omega). The platelet hyperreactivity state in the GHD-2 was reinforced by morphologic studies of electron microscopy. In conclusion, there were minor differences between the GHD-1 group and the controls, which might be due to the recovery of GH levels after therapy withdrawal. However, the maintained GHD group, despite minor cardiovascular risk index differences, has increased [Ca(2+)](i) and aggregation, which could indicate a hyperactivation state that might be viewed as an earlier marker of cardiovascular disturbancesen_US
dc.publisherThe Endocrine Societyen_US
dc.titlePlatelet hyperactivation in maintained growth hormone-deficient childhood patients after therapy withdrawal as a putative earlier marker of increased cardiovascular risken_US
item.fulltextCom Texto completo-
item.languageiso639-1en- of Pharmacy- - Center for Neuroscience and Cell Biology- - Center for Neuroscience and Cell Biology- - Center for Neuroscience and Cell Biology-
Appears in Collections:FCTUC Ciências da Vida - Artigos em Revistas Internacionais
Files in This Item:
File Description SizeFormat
Platelet hyperactivation in maintained growth.pdf337.57 kBAdobe PDFView/Open
Show simple item record


checked on Aug 2, 2022

Page view(s)

checked on Sep 27, 2022


checked on Sep 27, 2022

Google ScholarTM




Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.